RxDoctor Payments Data

Lydia McKenzie

Psychiatric/Mental Health · Plymouth, NHNPI 1386129856

Payments from drug & device makers

$1,283in general payments, 2019–2025

Across 59 payments — averaging $21.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Axsome Therapeutics, Inc.$118
  • Braeburn Inc.$63
  • Alkermes, Inc.$48
  • Neurocrine Biosciences, Inc.$23
  • Indivior Inc.$19

What the payments were for

  • Food & beverage$1,26999%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,283 in reported general payments places this provider in the 70th percentile of 264 psychiatric/mental health providers in New Hampshire.

See all psychiatric/mental health providers in New Hampshire

Medicare billing

Part B allowed, 2024
$32,394
Medicare patients
27
Services billed
830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl70$106,864
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl579$75,467
SuboxoneBuprenorphine Hcl/Naloxone Hcl101$35,500
Methylphenidate ErMethylphenidate Hcl24$2,732
Aripiprazole20$2,634
Duloxetine Hcl23$2,224
Clozapine37$1,554
Buprenorphine Hcl62$1,414
Venlafaxine Hcl ErVenlafaxine Hcl34$1,349
Lamotrigine81$1,124
Prazosin Hcl44$1,004
Bupropion XlBupropion Hcl37$624
Gabapentin83$598
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine15$455
Clonazepam56$375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,011$106,86470 claims
Indivior Inc.Suboxone$19$35,500101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 264 psychiatric/mental health providers in New Hampshire.

Other psychiatric/mental health in Plymouth

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →